DFTX Stock — Definium Therapeutics Inc. Common Shares: Cash, EV, Pipeline

Share price

$39.05

Market cap

$5,247.0M

Cash

$1,083.9M

Enterprise value

$4,199.6M

Balance sheet

Cash	$1,083.9M
Debt	$36.5M
Net cash	$1,047.4M
Enterprise value	$4,199.6M
Basic shares	134.4M shares
Fully diluted shares	156.2M shares
Fully diluted market cap	$6,099.2M
Cash per share	$8.06

Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.

Price history

Loading DFTX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 13 - Nov 24	DT120	Phase 3	Major Depressive Disorder	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

DT120

Phase 3 · Active Modality: small molecule (orally disintegrating tablet)

Aliases formerly MM120

Partnerships Catalent (exclusive license to Zydis ODT technology, August 2023); University Hospital Basel Liechti Lab License Agreement terminated (no further milestones or royalties owed; non-exclusive fully paid-up license retained)

Indications

Generalized anxiety disorder (GAD) (Phase 3)
Major depressive disorder (MDD) (Phase 3)
Posttraumatic stress disorder (PTSD) (Stage not disclosed)

Catalysts

— September 2026
— 2027

Status note Phase 2b GAD results announced December 2023; full results published in JAMA September 2025. FDA Breakthrough Designation for GAD (March 2024); UK MHRA Innovation Passport under ILAP for GAD (December 2024). Emerge Phase 3 in MDD topline Part A reported June 2026; Ascend Phase 3 in MDD first patient dosed May 2026. Planned Phase 3 program for PTSD (Haven study) expected to initiate in 2027.

DT402

Phase 2 · Active Modality: small molecule

Aliases R(-)-MDMA, formerly MM402

Indications

Autism spectrum disorder (ASD) (Phase 2)

Status note Phase 2a trial in ASD initiated fourth quarter 2025.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	DT120
Lead indication	Major Depressive Disorder
Lead phase	Phase 3
Active trials	5

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07592689	Phase 3	Recruiting	Sponsor	DFTX	—	Major Depressive Disorder	—
NCT06941844	Phase 3	Active, not recruiting	Sponsor	DFTX	—	Major Depressive Disorder	—
NCT06741228	Phase 3	Active, not recruiting	Sponsor	DFTX	—	Generalized Anxiety Disorder	—
NCT06809595	Phase 3	Active, not recruiting	Sponsor	DFTX	—	Generalized Anxiety Disorder	—
NCT07303907	Phase 2	Recruiting	Sponsor	DFTX	—	Autism Spectrum Disorder; ASD	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Definium Therapeutics US, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	400,000	+100,000	0.16%	2026-08-14
OrbiMed Advisors	365,400	-438,600	0.33%	2026-08-14
Logos Global Management	80,000	+80,000	0.16%	2026-08-14
Ikarian Capital	0	-58,803	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

DFTX — Definium Therapeutics Inc. Common Shares